Online inquiry

IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1170MR)

This product GTTS-WQ1170MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1170MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5875MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ14515MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ3863MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ4300MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ9125MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ2620MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 557
GTTS-WQ3253MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ2091MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AIN457
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW